Arterial Roadshow Session 7: How Innovative Companies Push Boundaries and Evolve — Sleep Therapy, Intelligent Follow-up, and Oncology Drug Innovation Deliver Breakthrough Solutions

Amid the fluctuations of the economic cycle, market self-discipline remains evident. Swept up by the massive waves of life sciences, intelligent manufacturing, and digital health, the ripples of innovation in pharmaceuticals, medical devices, and healthcare services continue to crash against the shores of capital. As capital and technology deepen their integration, contenders in the healthcare industry that possess both value and strength are emerging to the surface.

Driven by Intelligent Manufacturing, How Does Device Innovation Empower the Treatment of Insomnia and Depression?

How Does Service Innovation Drive the Development of Intelligent Follow-up Care in the Era of Digital Health?

How Can Drug Innovation Break Through the Bottlenecks in Cancer Diagnosis and Treatment with the Support of Life Sciences Technology?

In this edition of the VCBeat Roadshow Hall, we have curated five standout projects. Let’s explore how contenders that combine value with strength are continuously pushing boundaries and driving innovation within the evolving industrial and commercial landscape, amidst the rising tide of these three major technology clusters.

Bidirectional Intervention Protocol for Sleep Disorders and Depression

“4772 Nutrition Space” is the core product of Rongyu Technology, consisting of a nutrition capsule (service platform) and a carrier (personalized regimen). Clients conduct a sleep disorder screening for users based on medical standards. Based on the screening results, the type, stage, and characteristics of the user’s sleep disorder are determined, enabling personalized matching of a combination of 11 factor data points. This information is stored in the carrier. When the user inserts the carrier into the capsule, it activates the unit to deliver therapeutic services.

Currently, Rongyu Technology holds five invention patents related to climatotherapy, along with 28 other utility model and design patents. The company pioneered the establishment and release of enterprise standards for appropriate climatotherapy equipment in China. It is the only domestic enterprise that has obtained clinical data for climatotherapy equipment and filed for National Medical Products Administration (NMPA) certification for the treatment of sleep disorders and depression, thereby establishing substantial industry barriers. Therapeutically, the product addresses the long-standing issue of fragmented management of sleep disorders and depression, which often results in poor prognosis, drug side effects, and dependency. Mechanistically, it resolves the medical challenge of restoring and elevating brain-derived neurotrophic factor (BDNF) concentrations, which cannot be achieved through exogenous means.

Funding History: First Round of Financing

Funding Round: Pre-A

Financing Amount: RMB 15 Million

Use of Proceeds: Building Industry Barriers, R&D, Market Expansion, and Mass Production

Project Valuation: RMB 150 Million

Maternal and Child Health, Intelligent Follow-up, Medical Services

Beisheng specializes in post-discharge follow-up management for neonates and children with chronic diseases. Leveraging its leading cloud-based follow-up service platform, which integrates advanced technologies such as mobile health and the Internet of Things (IoT), Beisheng has established deep connectivity with multiple departments including Neonatology, Child Health Care, Hematology, Obstetrics, and Ophthalmology. This integration has formed a unique product matrix that provides comprehensive follow-up support through coordinated home-hospital collaboration. By combining professional online and offline assessment, monitoring, and intervention strategies, Beisheng delivers holistic follow-up management for pediatric patients.

Its unique product matrix includes the Intelligent Follow-up System for High-Risk Infants, the Early Childhood Development Management System, the Maternal and Child Health Care Management Platform, the Follow-up Support System for Pediatric Hematologic Diseases, the Pediatric Eye Health Management System, the Perinatal Research Follow-up Management Platform, a series of user follow-up mini-programs, and the O2LED Home Intelligent Pulse Oximeter. Among these, the Intelligent Follow-up System for High-Risk Infants is one of BB-care’s most distinctive products. It has been deployed across 22 provinces and municipalities in China and is one of the few systems nationwide that possess advanced data aggregation capabilities and follow-up decision support functionalities.

Financing History: Pre-A Round, Tens of Millions, Shanghai Science and Technology Venture Capital Co., Ltd.

Financing Round: Pre-A+

Financing Amount: RMB 10 million

Use of Funds: R&D, Operations, Product Promotion

Project Valuation: RMB 100 Million

Innovative Oncology Drug R&D, Liposomal Inhalants

Enkang Pharmaceutical was established in July 2017, with its subsidiaries, Inte Medicine and Enzhi Medicine, founded in 2014. The company focuses on the research and development of internationally leading innovative oncology drugs. As a spin-off from the Hong Kong University of Science and Technology, it effectively leverages academic R&D capabilities and has established two internationally leading technological platforms for innovative drug discovery.

Among these, the inhaled liposomal formulation platform was established based on inhaled liposomal cisplatin introduced by the company from the United States through technology transfer. To date, the company has leveraged this platform to develop eight new inhaled liposomal drug candidates and holds eight invention patents. The first drug candidate, ILC (Inhaled Liposomal Cisplatin), has completed Phase I and Phase II clinical trials abroad.

Additionally, the DRIP Inhibitor-Based Innovative Targeted Oncology Drug Screening Platform is an independently developed innovative oncology drug screening platform by Enkang Pharmaceutical. Drugs screened through this DRIP inhibitor platform can effectively target tumor cells without harming the majority of normal cells, featuring broad-spectrum activity, high efficacy, and low toxicity. The platform holds 18 domestic and international invention patents. Its first-in-class innovative small molecule, CM2, is currently in preclinical studies.

Financing Round: Series B

Financing Amount: $20 million

Use of Funds: Liposomal Inhalants, DRIP Inhibitor Oncology Drugs, Operational Management, Talent Acquisition

Early Cancer Screening, Quantum Dot POCT, Helicobacter pylori Typing

Xinsaiya is dedicated to the research, development, production, and clinical application of quantum dot-based POCT in vitro diagnostic products, establishing itself as one of the leading suppliers of quantum dot POCT IVD reagents in China. The performance of Xinsaiya’s ISIA quantum dot products rivals that of chemiluminescence assays; however, ISIA quantum dot technology offers broader application scenarios, greater flexibility and convenience, as well as lower acquisition and operational costs. Currently, the company has a mature product portfolio covering gastrointestinal disorders, bone metabolism, cardiovascular and cerebrovascular diseases, inflammation, and anemia testing.

The core members of the New Saiya team boast over 20 years of industry experience, with extensive expertise in immunodiagnostic technologies. They excel in differentiated product development strategies, as exemplified by their offerings for bone metabolism and gastric disease testing. The company’s Helicobacter pylori genotyping assay is a global exclusive, enabling early screening for gastric cancer. Additionally, its VEGF-based product for broad-spectrum cancer screening is scheduled for market launch next year.

Financing History: Angel Round (Individual Investors)

Funding Round: Pre-A

Financing Amount: RMB 30 million

Use of Proceeds: Project R&D, Regulatory Approval and Certification, Equipment Procurement, Marketing

Project Valuation: RMB 300 million

Chemical CRO, MAH License Holder, Cardiovascular and Cerebrovascular Diseases

Dongde Pharmaceutical was established in August 2013. In May 2018, it founded its MAH-licensed subsidiary, Chongqing Decheng Yongdao, specializing in cardiovascular and cerebrovascular diseases. The bioequivalence (BE) study for its first product, Ivabradine, has been successfully passed on the first attempt with excellent data performance. It is poised to become the first generic version approved in China and is expected to be launched and marketed in the second half of 2020. The company is currently advancing the development of subsequent products in its pipeline.

The company’s founder, Chen Xiaoyong, has 30 years of specialized experience in chemical synthesis and has received numerous honors, including the Second Prize of the National Science and Technology Progress Award, the First Prize of the Sichuan Provincial Science and Technology Progress Award, and the First Prize of the Chongqing Municipal Science and Technology Progress Award. The core R&D team, which holds equity stakes in the company, is highly efficient and stable; over more than a decade of collaboration, it has developed more than ten drugs that were the first domestic generics in China. The company’s business model is currently transitioning from contract research and development to holding its own marketing authorizations. In the future, it will focus on addressing unmet clinical needs by developing “small but beautiful” products with significant technical barriers, ultimately establishing a structure comprising “one core R&D team” plus “multiple license-holding companies for various indications.”

Financing History: Angel Round (Individual Investors)

Funding Round: Pre-A

Financing Amount: RMB 50 million

Use of Funds: New Drug R&D, Equity Structure Adjustment

Project Valuation: RMB 100 Million

Interested parties, please contact the fundraising assistant Xiao Yun: DongMai_Investent